Clarapath Launches Its Latest Platform for Automated Tissue Sectioning

BCW Member Clarapath, a leader in solutions for anatomic pathology, recently announced the latest release of SectionStar™, the next-generation version of its robotic microtomy platform. Robotic microtomy refers to the use of automated or robotic technology to perform microtomy, which is the process of cutting extremely thin slices of tissue for examination

SectionStar is FDA-registered and listed for clinical use and is now being deployed in laboratory environments to support increasing case volumes and staffing pressures while helping standardize one of the most technically demanding steps in histology, which is the study of tissue at the microscopic level.

Building on the success of the original SectionStar system, this new release was developed in close collaboration with histotechnologists and pathology laboratories to address the complexities of tissue sectioning. The updated platform introduces enhancements across hardware, software, and user experience which are designed to help laboratories improve efficiency, consistency, and turnaround times.

“This version of the SectionStar platform represents a major step forward for Clarapath and for the clinical laboratories we serve,” said Eric Feinstein, President and CEO of Clarapath. “By continuing to listen to the challenges our customers face, we are able to innovate in ways that meet the operational and regulatory demands of clinical histology while delivering meaningful improvements in reliability and ease of use.”

Key Enhancements to SectionStar Include: improved sectioning consistency and reliability to support clinical and research applications; enhanced software and user interface updates designed to streamline daily operation and training; greater system robustness and serviceability, supporting higher-throughput laboratory environments and expanded workflow options to better align with existing clinical histology processes for workflow optimization.

“Automation in histology isn’t about replacing expertise — it’s about supporting it,” added Matthew Claster, Chief Business Officer at Clarapath.  “With the innovative products we are developing at Clarapath, laboratories can deploy rigorously tested automation platforms that help deliver consistent, repeatable sections while allowing skilled histotechnologists to focus on higher-value work.”